• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

视网膜类器官的光反应性:现状与未来机遇。

Retinal organoid light responsivity: current status and future opportunities.

机构信息

Department of Biology, The University of Akron, Akron, Ohio.

CellSight Ocular Stem Cell and Regeneration Program, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, Colorado.

出版信息

Transl Res. 2022 Dec;250:98-111. doi: 10.1016/j.trsl.2022.06.001. Epub 2022 Jun 9.

DOI:10.1016/j.trsl.2022.06.001
PMID:35690342
Abstract

The ability to generate human retinas in vitro from pluripotent stem cells opened unprecedented opportunities for basic science and for the development of therapeutic approaches for retinal degenerative diseases. Retinal organoid models not only mimic the histoarchitecture and cellular composition of the native retina, but they can achieve a remarkable level of maturation that allows them to respond to light stimulation. However, studies evaluating the nature, magnitude, and properties of light-evoked responsivity from each cell type, in each retinal organoid layer, have been sparse. In this review we discuss the current understanding of retinal organoid function, the technologies used for functional assessment in human retinal organoids, and the challenges and opportunities that lie ahead.

摘要

从多能干细胞体外生成人类视网膜为基础科学和开发治疗视网膜退行性疾病的方法提供了前所未有的机会。视网膜类器官模型不仅模拟了天然视网膜的组织架构和细胞组成,而且可以达到惊人的成熟水平,使其能够对光刺激产生反应。然而,评估每个视网膜类器官层中每种细胞类型的光诱发反应的性质、幅度和特性的研究还很少。在这篇综述中,我们讨论了对视网膜类器官功能的现有理解、用于人类视网膜类器官功能评估的技术,以及未来的挑战和机遇。

相似文献

1
Retinal organoid light responsivity: current status and future opportunities.视网膜类器官的光反应性:现状与未来机遇。
Transl Res. 2022 Dec;250:98-111. doi: 10.1016/j.trsl.2022.06.001. Epub 2022 Jun 9.
2
A highly reproducible and efficient method for retinal organoid differentiation from human pluripotent stem cells.一种高度可重现且高效的方法,用于从人类多能干细胞中分化出视网膜类器官。
Proc Natl Acad Sci U S A. 2024 Jun 18;121(25):e2317285121. doi: 10.1073/pnas.2317285121. Epub 2024 Jun 13.
3
Differentiation of retinal organoids from human pluripotent stem cells.人多能干细胞来源的视网膜类器官的分化。
Methods Cell Biol. 2020;159:279-302. doi: 10.1016/bs.mcb.2020.02.005. Epub 2020 Mar 11.
4
Retinal organoids in disease modeling and drug discovery: Opportunities and challenges.视网膜类器官在疾病建模和药物发现中的应用:机遇与挑战。
Surv Ophthalmol. 2024 Mar-Apr;69(2):179-189. doi: 10.1016/j.survophthal.2023.09.003. Epub 2023 Sep 29.
5
Comprehensive characterization of fetal and mature retinal cell identity to assess the fidelity of retinal organoids.全面鉴定胎儿和成熟视网膜细胞的特征,以评估视网膜类器官的保真度。
Stem Cell Reports. 2023 Jan 10;18(1):175-189. doi: 10.1016/j.stemcr.2022.12.002.
6
Comparison of Developmental Dynamics in Human Fetal Retina and Human Pluripotent Stem Cell-Derived Retinal Tissue.人类胎儿视网膜与人类多能干细胞衍生视网膜组织的发育动力学比较。
Stem Cells Dev. 2021 Apr;30(8):399-417. doi: 10.1089/scd.2020.0085.
7
Accelerated and Improved Differentiation of Retinal Organoids from Pluripotent Stem Cells in Rotating-Wall Vessel Bioreactors.旋转壁式生物反应器中多能干细胞来源的视网膜类器官的快速高效分化。
Stem Cell Reports. 2018 Jan 9;10(1):300-313. doi: 10.1016/j.stemcr.2017.11.001. Epub 2017 Dec 7.
8
Rapid and efficient generation of mature retinal organoids derived from human pluripotent stem cells via optimized pharmacological modulation of Sonic hedgehog, activin A, and retinoic acid signal transduction.通过优化 Sonic hedgehog、激活素 A 和视黄酸信号转导的药理学调节,从人多能干细胞快速有效地生成成熟的视网膜类器官。
PLoS One. 2024 Aug 9;19(8):e0308743. doi: 10.1371/journal.pone.0308743. eCollection 2024.
9
Organoid technology for retinal repair.用于视网膜修复的类器官技术。
Dev Biol. 2018 Jan 15;433(2):132-143. doi: 10.1016/j.ydbio.2017.09.028. Epub 2017 Dec 25.
10
Cell Types of the Human Retina and Its Organoids at Single-Cell Resolution.人类视网膜及其类器官的细胞类型解析
Cell. 2020 Sep 17;182(6):1623-1640.e34. doi: 10.1016/j.cell.2020.08.013.

引用本文的文献

1
Exploring organoid and assembloid technologies: a focus on retina and brain.探索类器官和组装体技术:聚焦于视网膜和大脑。
Expert Rev Mol Med. 2025 Mar 27;27:e14. doi: 10.1017/erm.2025.9.
2
H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration.H105A肽眼药水可促进视网膜变性小鼠和人类模型中的光感受器存活。
Commun Med (Lond). 2025 Mar 21;5(1):81. doi: 10.1038/s43856-025-00789-8.
3
Retinal Organoids from Induced Pluripotent Stem Cells of Patients with Inherited Retinal Diseases: A Systematic Review.
来自遗传性视网膜疾病患者诱导多能干细胞的视网膜类器官:一项系统综述。
Stem Cell Rev Rep. 2025 Jan;21(1):167-197. doi: 10.1007/s12015-024-10802-7. Epub 2024 Oct 18.
4
Generating ESC-Derived RGCs for Cell Replacement Therapy.生成 ESC 衍生的 RGC 用于细胞替代治疗。
Methods Mol Biol. 2025;2848:187-196. doi: 10.1007/978-1-0716-4087-6_12.
5
H105A peptide eye drops promote photoreceptor survival in murine and human models of retinal degeneration.H105A肽眼药水可促进视网膜变性小鼠和人类模型中的光感受器存活。
bioRxiv. 2024 Jul 16:2024.07.10.602890. doi: 10.1101/2024.07.10.602890.
6
A treatment within sight: challenges in the development of stem cell-derived photoreceptor therapies for retinal degenerative diseases.一种即将实现的治疗方法:视网膜退行性疾病干细胞衍生光感受器疗法开发中的挑战
Front Transplant. 2023 Sep 29;2:1130086. doi: 10.3389/frtra.2023.1130086. eCollection 2023.
7
Retinal Ciliopathies and Potential Gene Therapies: A Focus on Human iPSC-Derived Organoid Models.视网膜纤毛病与潜在的基因疗法:聚焦于人类诱导多能干细胞衍生的类器官模型
Int J Mol Sci. 2024 Mar 1;25(5):2887. doi: 10.3390/ijms25052887.
8
Modeling complex age-related eye disease.建模复杂的与年龄相关的眼病。
Prog Retin Eye Res. 2024 May;100:101247. doi: 10.1016/j.preteyeres.2024.101247. Epub 2024 Feb 15.
9
Retinal Organoids: A Next-Generation Platform for High-Throughput Drug Discovery.视网膜类器官:高通量药物发现的新一代平台。
Stem Cell Rev Rep. 2024 Feb;20(2):495-508. doi: 10.1007/s12015-023-10661-8. Epub 2023 Dec 11.
10
Advancements in 2D and 3D In Vitro Models for Studying Neuromuscular Diseases.二维和三维体外模型在神经肌肉疾病研究中的进展。
Int J Mol Sci. 2023 Nov 30;24(23):17006. doi: 10.3390/ijms242317006.